scholarly journals A rare transition of non-Hodgkin lymphoma into classical Hodgkin disease

2016 ◽  
Vol 2 (5) ◽  
pp. 242
Author(s):  
Editorial Office

<div>An uncommon case of blood cancer non-Hodg- kin lymphoma developing into classical  Hodgkin lymphoma was recently described by researchers from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in a case report published in this issue of AMOR.</div><p> </p><p>“Through a series of biopsies, we report a unique case of diffuse large B-cell lymphoma (DLBCL) with stepwise development of classical Hodgkin lymphoma (cHL),” said pathologists Dr. Haipeng Shao and Pardis Vafaii from the Department of Hematopathology and Laboratory Medicine. “To the best of our knowledge, this is the first report of an intermediate stage of transformation from DLBCL into cHL,” they added.</p><p> </p><p>Lymphoma, or cancer in the infection-fighting lymphatic part of a human’s immune system, is categorized into two types: Hodgkin lymphoma and non-Hodgkin lymphoma – both with distinct behaviors and different treatment requirements. Classical Hodgkin lymphoma – named after the 19<sup>th</sup> century British physician Thomas Hodgkin who first described the abnormalities in lymphatic system – is a less frequently diagnosed lymphoma subtype with tell-tale signs of abnormal lymphoid cells called ‘Reed­Sternberg cells’ which are observed as giant purple nucleoli when examined under light microscopy.</p><p> </p><p>However, 90% of lymphomas are of the non-Hodgkin lymphoma variety and do not exhibit the Reed­Sternberg cells. Of all the non-Hodgkin lymphomas, DLBCL is the most common type, which develops when white blood cells called lymphocytes (specifically the B-cell lymphocytes) start dividing uncontrollably. The distinction between DLBCL and cHL is clinically important as both respond differently to chemotherapeutic regimens, according to Shao and Vafaii. Moreover, “classical Hodgkin lymphoma and non-Hodgkin lymphoma rarely develop in the same patient,” they explained.</p><p> </p><p>In their published case report, however, DLBCL and cHL was found to develop on the same anatomic sites, particularly on the skin of the patient, evidenced by the presence of cHL following the occurrence of DLBCL. The patient was an elderly male with a history of stage IV DLBCL. Biopsies taken from the patient’s left arm and upper back revealed results consistent with DLBCL of the non-germinal center subtype. The patient then underwent chemotherapy, salvage therapy, and an autologous bone marrow transplant. Following the transplant, the patient’s biopsies started manifesting features of cHL, indicating a hybrid intermediate stage, according to the authors. “In the second biopsy…scattered Reed -Sternberg/Hodgkin-like cells were admixed with the DLBCL cells,” Shao and Vafaii wrote of the large atypical lymphoid cells which resemble Reed-Sternberg in cHL but do not develop into cHL.</p><p> </p><p>Nonetheless, despite these Reed-Sternberg/Hodgkin- like cells showing typical immunophenotype of cHL cells and were associated with limited inflammatory cells, “cHL diagnosis requires the presence of expansile lesion with a characteristic mixed inflammatory background as- sociated with Reed-Sternberg/Hodgkin cells,” the authors explained, and “the Reed-Sternberg/Hodgkin-like cells did not seem to elicit a mixed inflammatory reaction and form a discrete mass lesion within the large lymphoid cells,” hence rendering it difficult for the pathologists to diagnose cHL at this stage.</p><p> </p><p>Three months later, however, an excisional biopsy performed on the patient’s lymph node no longer showed evidence of DLBCL but instead exhibited “many scattered clusters of Reed-Sternberg/Hodgkin cells with prominent cherry-red nucleoli in a background of small mature lymphocytes and granulocytes,” which are findings consistent with a cHL of the nodular sclerosis subtype, Shao and Vafaii reported.</p><p> </p><p>The diagnosis of cHL established in the final lymph node biopsy therefore demonstrated that the Reed- Sternberg/Hodgkin-like cells found in the intermediate stage signaled the progression of DLBCL into cHL. “While Reed-Sternberg/Hodgkin-like cells are not uncommonly seen in a variety of non-Hodgkin lymphomas, the subsequent development of cHL in this patient indicated that the scattered Reed-Sternberg/Hodgkin cells among DLBCL cells truly represented a precursor of cHL,” the authors said, adding that the transformation would be possible for pathologists to diagnose, albeit very challenging.</p><p> </p><p>Furthermore, “the identification of a hybrid intermediate stage suggested that [cHL and DLBCL] were clonally related,” they said. Further analysis of the genetic changes responsible for cHL transformation could possibly be done by examining individual Reed-Sternberg/ Hodgkin-like cells in the precursor stage, as well as the cHL cells in later stages, with subsequent molecular studies such as laser capture microdissection or next generation sequencing, their report proposed.</p><p> </p><p>According to Shao and Vafaii, the case report was unique in which a stepwise transformation from DLBCL into cHL was demonstrated through a series of biopsies, which highlights the importance of repeated biopsies in diagnostically-challenging case. “Precursor or early lesions that could not be initially established diagnostically would eventually manifest themselves in later biopsies,” the authors concluded. </p><div> </div><p> </p>

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4633-4633
Author(s):  
Ling Chen ◽  
Yaling Yang ◽  
C. Cameron Yin ◽  
Gary Lu ◽  
Su Chen ◽  
...  

Abstract Abstract 4633 Background: Golgins are proteins of the Golgi complex. Several Golgins have been implicated in apoptosis. Expression of Golgin-84, a Golgin protein, is altered in apoptotic WEHI-231, a B-cell lymphoma line, suggesting that Golgin-84 may play a role in lymphoid tumorigenesis. Here, we aimed to determine the expression levels of Golgin-84 in human primary non-Hodgkin lymphomas and plasma cell myeloma. Design: Golgin-84 expression was investigated in non-Hodgkin lymphoma cell lines by using Western blot analysis and polyclonal antibodies. Using immunohistochemical stains, Western blotting analysis and Q-PCR, Golgin-84 expression was assessed in 5 reactive lymph nodes, 149 cases of primary non-Hodgkin lymphoma and 28 cases of primary plasma cell myeloma. Results: Immunohistochemical stains, Western blotting analysis and Q-PCR on 5 reactive lymph nodes demonstrated that Golgin-84 was expressed at low levels in lymphoid cells of germinal centers, mantle cells, marginal zones, and interfollicular areas. Golgin-84 was variably expressed in non-Hodgkin lymphoma cell lines tested, with the highest levels in cells from high-grade tumors (e.g. anaplastic large cell lymphoma; ALCL, Diffuse large B-cell lymphoma (DLBCL), ALCL and peripheral T-cell lymphoma unspecified (PTCL)) and the lowest levels in mantle cell lymphoma (MCL) cells. DLBCL, ALCL and PTCL frequently showed high expression of Golgin-84. Most lymphoplasmacytic lymphomas (LPL) and plasma cell myeloma (PCM) expressed high levels of Golgin-84. Expression levels of Golgin-84 were lower in MCL and low-grade B-cell non-Hodgkin lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). Conclusions: Golgin-84 expression levels are low in lymphoid cells of normal lymph nodes. Most (>90%) cases of LPL and PCM, and at least half of cases of DLBCL, ALCL and PTCL express high levels of Golgin-84. These findings suggest that Golgin-84 may be involved in tumorigenesis or lymphoma progression, particularly in neoplasms with plasmacytic differentiation. Disclosures: No relevant conflicts of interest to declare.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e19536-e19536
Author(s):  
Lawrence Weiss ◽  
Alexander Bordwell ◽  
Alex Corwin ◽  
Dave Henderson ◽  
Denise Hollman- Hewgley ◽  
...  

e19536 Background: Routine diagnosis of classical Hodgkin lymphoma is performed with a panel of immunohistochemistry markers to evaluate the biomarker expression profile of the relatively rare Hodgkin cells. One of the key challenges of this technique is that serial immunostains are used and hence it can be difficult or impossible to locate the same Hodgkin cell on adjacent slides. Given the rarity of the Hodgkin cells coupled with the number of markers that are needed for a definitive diagnosis, we developed a new technique in which a single patient slide is multiplexed with nine different antibodies . Methods: One FFPE tissue section from 11 cases was probed for the following nine biomarkers: CD30, CD15, CD45, Pax5, CD20, CD79a, OCT2, Bob1, and CD3. An initial 10x whole slide fluorescent image of CD30 was acquired and presented to the pathologist who based on this staining selected regions of interest for higher magnification (40x) imaging of the CD30 and the other antibodies. The fluorescent images acquired were processed for interpretation using an in-house developed viewing tool. The pathologist was able to view each biomarker as a standard grayscale, monochromatic image, an overlay of two or more biomarkers, or as a virtually created molecular DAB image. Results: A correct diagnosis of classical Hodgkin lymphoma vs. other was able to be made using the MultiOmyx platform in all cases. Subjectively, the pathologist noted that the novel methodology allowed for a significantly more confident assessment of marker expression on the Hodgkin cells in the seven cases of classical Hodgkin lymphoma, eliminating many issues of staining ambiguity and allowing recognition of subtle nuances of staining intensity in the Hodgkin cells. The CD30+ cells in the four other cases, three cases of B-cell lymphoma and one case of lymphocyte predominance Hodgkin lymphoma, showed a B-cell profile that was distinguishable from the classical Hodgkin cell phenotype. Conclusions: This new method of fluorescent multiplexing on a single tissue section allows more accurate interpretation of the biomarker expression profile on the same Hodgkin cell. It is likely that this paradigm can be expanded to a greater range of challenging cases in hematopathology.


2016 ◽  
Vol 2 (5) ◽  
pp. 292
Author(s):  
Pardis Vafaii ◽  
Haipeng Shao

Classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma rarely develop in the same patient synchronously or metachronously. Through a series of biopsies, we report a unique case of diffuse large B-cell lymphoma (DLBCL) with stepwise development of classical Hodgkin lymphoma. An intermediate stage of transformation was identified with scattered Reed-Sternberg/Hodgkin cells present in a background of the DLBCL cells. These Reed- Sternberg/Hodgkin cells showed typical immunophenotype of cHL cells and were associated with limited inflammatory cells. While Reed-Sternberg/Hodgkin-like cells are not uncommonly seen in a variety of non-Hodgkin lymphomas, the subsequent development of cHL in this patient indicated that the scattered Reed-Sternberg/Hodgkin cells among DLBCL cells truly represented a precursor of cHL. This would be extremely challenging, if not impossible, for pathologists to diagnose. We also highlight the importance of clinicopathological correlation and the crucial role of additional biopsies.


2020 ◽  
Vol 8 ◽  
pp. 232470962094131
Author(s):  
Ishan Patel ◽  
Arda Akoluk ◽  
Vandan Upadhyaya ◽  
Shraddhadevi Makadia ◽  
Steven Douedi ◽  
...  

Gray zone lymphoma, also known as B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, is a rare malignancy with overlapping features of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma. Most commonly mediastinal involvement is seen. Extranodal involvement is rare. In this case report, we present the case of a 59-year-old male who presented with stress-related left shoulder pain, ultimately diagnosed with gray zone lymphoma. The patient was treated with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin-rituximab (EPOCH-R) regimen followed by consolidation radiotherapy resulting in complete response. We are highlighting this case as rare and atypical presentation of a rare disease.


2020 ◽  
Vol 1 (2) ◽  
Author(s):  
Bamidele J. Alegbeleye ◽  
Olorunseun O. Ogunwobi

BACKGROUND: Breast lymphomas are rare extranodal lymphomas. They constitute a tiny percentage of malignant tumors of the breast and a small subset of extranodal lymphomas. The rarity of breast lymphomas is attributed to the very scanty lymphoid tissue content of the chest wall. AIMS OF STUDY: This case report aims to provide an up-to-date review of the literature on breast lymphomas and clinicians to consider the possibility of this disease entity while treating a breast mass. CASE PRESENTATION: A case is reported of primary mammary non-Hodgkin lymphoma in a 52-year-old man. Fine needle aspiration cytology (FNAC) was inconclusive. Incisional biopsy-confirmed primary breast lymphoma was diagnosed as the diffuse large B-cell type: non – Hodgkin lymphoma. He had complete disease remission in response to chemotherapy – Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (CHOP). After that, the patient did not require further surgical intervention. He was followed up at two-monthly intervals for eighteen months in the surgical outpatient clinic with no disease recurrence and satisfactory clinical outcome, following which he discontinued follow-up visits. CONCLUSION: While assessing breast masses, clinicians must recognize primary non-Hodgkin lymphoma as a potential differential diagnosis. A core biopsy of breast masses is needed to exclude it, and appropriate treatment must be given if diagnosed.


Blood ◽  
2012 ◽  
Vol 119 (15) ◽  
pp. 3503-3511 ◽  
Author(s):  
Linka Xie ◽  
Alexey Ushmorov ◽  
Frank Leithäuser ◽  
Hanfeng Guan ◽  
Christian Steidl ◽  
...  

Abstract The FOXO transcription factors control proliferation and apoptosis in different cell types. Their activity is regulated by posttranslational modifications, mainly by the PI3K-PKB pathway, which controls nuclear export and degradation. We show that FOXO1 is highly expressed in normal germinal center B cells as well as in non-Hodgkin lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma, mucosa-associated lymphoid tissue non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemia, and mantle cell lymphoma. In contrast, in 31 of 32 classical Hodgkin lymphoma (cHL) cases, Hodgkin and Reed-Sternberg cells were FOXO1 negative. Neoplastic cells of nodular lymphocyte-predominant Hodgkin lymphoma were negative in 14 of 20 cases. FOXO1 was down-regulated in cHL cell lines, whereas it was expressed in non-Hodgkin lymphoma cell lines at levels comparable with normal B cells. Ectopic expression of a constitutively active FOXO1 induced apoptosis in cHL cell lines and blocked proliferation, accompanied with cell-cycle arrest in the G0/G1 phase. We found that, in cHL cell lines, FOXO1 is inactivated by multiple mechanisms, including constitutive activation of AKT/PKB and MAPK/ERK kinases and up-regulation of microRNAs miR-96, miR-182, and miR-183. These results suggest that FOXO1 repression contributes to cHL lymphomagenesis.


2011 ◽  
Vol 2 (1) ◽  
pp. 53-55
Author(s):  
Gururaj Patil Bheemanagouda ◽  
Kaveri Satish Hallikeri ◽  
Rekha Pillai Krishna

ABSTRACT Non-Hodgkin lymphomas are a group of highly diverse malignancies with great tendency to affect organs and tissues that do not ordinarily contain lymphoid cells. T-cell/histiocyte-rich large B-cell lymphoma (TCRBCL) is an uncommon histological variant of large B-cell non- Hodgkin lymphoma, morphologically characterized by a minor population of clonal B-cells distributed in a background of prominent reactive T lymphocytes. This is an interesting case of extranodal isolated TCRBCL in jaw bone and to our knowledge this is the first report of its kind in a nonimmune compromised 40-year-old female. An increase in the number of case reports of non-Hodgkin lymphoma in head and neck region definitely makes it to be included as differential diagnosis. The patient has completed 5 years of therapy with no evidence of recurrence.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2994-2994 ◽  
Author(s):  
Alisha Adams ◽  
Alexander Bordwell ◽  
Derek Bouman ◽  
Deanna Fisher ◽  
Denise Hollman ◽  
...  

Abstract Background/Introduction The diagnosis of classical Hodgkin lymphoma is often difficult to establish due to the rarity of the neoplastic component and the necessity to perform immunostains on serial sections. We have developed a fluorescent multiplexed methodology in formalin-fixed, paraffin-embedded sections which enables assessment of multiple antigens on a single tissue section and allows evaluation of specific cells within specific fields (MultiOmyxTM). In this clinical application, we assessed CD30-positive cells with eight additional antibodies on the same piece of tissue as an aid to the diagnosis of classical Hodgkin lymphoma. Methods One formalin-fixed tissue section from each of the 56 cases was probed with fluorescently conjugated antibodies against the following nine biomarkers: CD30, CD15, CD45, Pax5, CD20, CD79a, OCT2, Bob1, and CD3 (Fig. 1). An initial 10x whole slide fluorescent image of CD30 was acquired and presented to the pathologist who, based on this staining, selected regions of interest for higher magnification (40x) imaging of the CD30 and the other antibodies to facilitate assessment. The fluorescent images acquired were processed for interpretation using an in-house developed viewing tool. The pathologist was able to view each biomarker as a standard grayscale, monochromatic image, an overlay of two or more biomarkers, or as an algorithmically generated molecular diaminobenzidine (DAB) image resembling a bright field approach. Results The staining characteristics were studied in a series of 23 cases. Individual antibody specificity was found to be 100% in all but one marker assessed; CD30 was found to be discordant in 1 of the 23 samples. Inter- and intraday concordance was 100%. Fifty-six unique cases were studied for diagnostic concordance. We compared historical diagnosis using immunohistochemistry to the MultiOmyxTM diagnosis, studying blinded cases of classical Hodgkin lymphoma and other differential diagnosis entities. Additionally, we included nodular lymphocyte predominance Hodgkin lymphoma, T-cell rich B-cell lymphoma, peripheral T-cell lymphoma, including anaplastic large cell lymphoma, and reactive immunoblastic proliferations. Fifty-four of the 56 cases showed complete concordance. One case was diagnosed as equivocal on initial historical diagnosis, but subsequent rebiopsy diagnosis showed concordance with the MultiOmyxTM diagnosis derived from the initial specimen. One other case was discordant with the historical diagnosis (case was studied five independent times by MultiOmyxTM, all with same diagnosis), and retrospective analysis of the case raised doubt as to the validity of the historical diagnosis. Discussion MultiOmyxTM single slide assay has similar staining characteristics and is at least equivalent to standard immunohistochemical stains. It allows for better correlation of results between stains in a given case, particularly in cases with rare Hodgkin cells, since it allows direct comparison of stains within the same field of view and on the same cells. In addition, MultiOmyxTM may be advantageous in small samples, in which full immunohistochemical profiles may not be possible. MultiOmyxTM allowed improved assessment of Hodgkin cells for antigens expressed on other cell types (e.g., B-cell antigens on reactive immunoblasts, or CD15 on reactive histiocytes), as well as antigens expressed on directly adjacent cells (e.g., CD45 and CD3). This novel methodology is practical for routine diagnosis, and will likely be an aid to the improved diagnosis of Hodgkin lymphoma. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document